Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) https://validator.w3.org/feed/docs/rss2.html IMMUNOLOGY SEMINAR: PEPTIDE CANCER VACCINE EXPERIENCE AT NCI Thailand Hub of Talents in Cancer Immunotherapy (TTCI Thailand) Member Contents Our Team Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy Basic Cancer Immunology for Clinicians CAR T-cell Immunometabolism: Insights from Patients AP-SciBio 2027 x WIC APAC 2027 & Thai Immunology Annual Meeting Antibody-Drug Conjugates (ADCs): Recent Advances in the Treatment of Solid Tumors A Trispecific Antibody Induces Potent Tumor-Directed T-Cell Activation and Antitumor Activity by CD3/CD28 Co-Engagement CD70 CAR T cells secreting an anti-CD33/anti-CD3 dual-targeting antibody overcome antigen heterogeneity in AML TTCI at a glance Chiang Mai University Team Mahidol University Team NRCT Hosts Seminar on “Thai Cancer Immunotherapy: Collaboration, Regulation, and the Future of Treatment” at MHESI Fair 2025 Thai Immunology Annual Meeting 2026 IPOPI | SEAPID | Chulalongkorn | Erasmus MC Meeting 2026 International Collaborator Pediatric Neuro-Oncology Consortium – Chulalongkorn University Research Forum Scientific Meeting: Medical Applications of Gene Editing and Synthetic Biology Technologies CAR T-cell therapy for paediatric solid tumours: clinical trial development and preclinical modelling TTCI to Participate in WIC-APAC 2026 Patient Care and Toxicities Management of CAR T-cell in Pediatrics TTCI Webinar “CAR T-cell Immunometabolism, Insights from Patients” White Paper Equipment Personalized Cancer Vaccines – A New Frontier in Thailand’s Fight Against Cancer Government Agencies and Related Announcements Enhancing T cell cytotoxicity against lung cancer with an αPD-L1 protein engager and gemcitabine combination therapy Enhancing T cell cytotoxicity in multiple myeloma with bispecific αPD-L1 × αCD3 T cell engager-armed T cells and low-dose bortezomib therapy Registration Open: 1st International Scientific Symposium in Hematologic Malignancy (CETH, Chulalongkorn University) Khonkaen University Team University of Wisconsin School of Medicine and Public Health Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody Thammasat University Team Chulalongkorn University Team Efficiently targeting folate receptor alpha-positive ovarian cancer by human antibody VH domain-based chimeric antigen receptor (CAR) A multi-center clinical research project to study the Safety and Efficacy of CD19 CAR T-cells in ALL (Acute Lymphoblastic Leukemia) by Academic Hubs Celebrating Excellence in Immunotherapy: Dr. Piriya Luangwattananun Honored as Young Investigator New Immune Cell Engager Combined with Chemotherapy Boosts Attack on Multiple Myeloma Researchers Develop Method to Remove Specific Problematic Proteins for Improved Drug Effects Antitumor activities of chimeric antigen receptor T cells targeting Mucin-1 with self-released anti-PD-1 IgG antibody Enhancing Innate and Adaptive Immunity to Combat Multiple Myeloma: Combined Use of Trispecific NK Cell Engagers (TriKEs) and Bispecific T-Cell Engagers (BiTEs) in Immunotherapy New Dual-Targeting Protein and Chemotherapy Boost T-Cell Attack on Lung Cancer TTCI Members Receive Research Recognition Awards from Faculty of Sciences, Chiang Mai University Vaccine and Therapeutic RNA Research Forum 2025 Announcement: Student Progress Report 1/2025 Special Lecture: Advanced Cellular Therapeutics for Hematologic Malignancies Chula Licenses Thai PD-1 Antibody to US Biopharma TTCI Representative Highlights CAR-T Cell Therapy Roadmap at the 74th JSTMCT Annual Meeting in Yokohama